Wedbush Downgrades Tourmaline Bio (TRML) to Neutral Post Acquisition
Tweet Send to a Friend
Wedbush analyst Laura Chico downgraded Tourmaline Bio (NASDAQ: TRML) from Outperform to Neutral with a price target of $48.00.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
